mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

Completed

Conditions studied: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction

In brief

To determine if patients with a history of Diabetes Mellitus Type I or II developed a change in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within the first week following administration of each dose of the COVID-19 vaccine.

Key facts

Study ID

NCT04923386

Run by

Levenson, David I., M.D.

People needed

25

Starts

2021-06-15

Expected to finish

2022-02-01

Last updated by the study team

2022-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Diabetes Mellitus Type I or Type II
• Received the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine

You may not qualify if…

• Patients <18y/o.
• Patients that did not receive a COVID-19 vaccine.
• Patients who did not have a CGMS downloaded for a week prior and a week after vaccination.

Where it is running

• East Coast Medical Associates — Boca Raton, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.